FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969373323> ?p ?o ?g. }

• W2969373323 endingPage "e027860" @default.
• W2969373323 startingPage "e027860" @default.
• W2969373323 abstract "Introduction Overtreatment of localised prostate cancer is substantial despite increased use of active surveillance. No randomised trials help define how to monitor patients or when to initiate treatment with curative intent. Methods and analysis A randomised, multicentre, intervention trial designed to evaluate the safety of an MRI-based active surveillance protocol, with standardised triggers for repeated biopsies and radical treatment. The aim is to reduce overtreatment of prostate cancer. 2000 men will be randomly allocated to either surveillance according to current practice or to standardised triggers at centres in Sweden, Norway, Finland and the UK. Men diagnosed in the past 12 months with prostate cancer, ≤T2a, prostate-specific antigen (PSA) <15 ng/mL, PSA density ≤0.2 ng/mL/cc, any International Society of Urological Pathology (ISUP) grade 1 are eligible. Men with ISUP grade 2 in <30% of cores on systematic biopsy and <10 mm cancer in one core on systematic or targeted biopsy are also eligible. Men diagnosed on systematic biopsy should have an MRI and targeted biopsies against Prostate Imaging and Reporting Data System V.2 3–5 lesions before inclusion. Identical follow-up in the two study arms: biannual PSA testing, yearly clinical examination and MRI every second year. In the experimental arm, standardised triggers based on MRI and PSA density elicit repeated biopsies. MRI and histopathological progression trigger radical treatment. Primary outcome measure is progression-free survival. Secondary outcome measures are cumulative incidence of metastatic disease, treatments with curative intent, pT3-4 at radical prostatectomy, switch to watchful waiting, prostate cancer mortality and quality of life. Inclusion started in October 2016 and in October 2018; 275 patients have been enrolled. Ethics and dissemination Ethical approval was obtained in each participating country. Results for the primary and secondary outcome measures will be submitted for publication in peer-reviewed journals. Trial registration number NCT02914873 ." @default.
• W2969373323 created "2019-08-29" @default.
• W2969373323 creator A5001406891 @default.
• W2969373323 creator A5003951535 @default.
• W2969373323 creator A5008940864 @default.
• W2969373323 creator A5010246954 @default.
• W2969373323 creator A5017833700 @default.
• W2969373323 creator A5031651345 @default.
• W2969373323 creator A5033637479 @default.
• W2969373323 creator A5037739817 @default.
• W2969373323 creator A5047898396 @default.
• W2969373323 creator A5053328244 @default.
• W2969373323 creator A5054505998 @default.
• W2969373323 creator A5060939609 @default.
• W2969373323 creator A5066405171 @default.
• W2969373323 creator A5073171755 @default.
• W2969373323 creator A5076457123 @default.
• W2969373323 creator A5081195789 @default.
• W2969373323 date "2019-08-01" @default.
• W2969373323 modified "2023-10-17" @default.
• W2969373323 title "PCASTt/SPCG-17—a randomised trial of active surveillance in prostate cancer: rationale and design" @default.
• W2969373323 cites W1177136027 @default.
• W2969373323 cites W160262423 @default.
• W2969373323 cites W1827911007 @default.
• W2969373323 cites W1964223543 @default.
• W2969373323 cites W1966393201 @default.
• W2969373323 cites W2021480933 @default.
• W2969373323 cites W2035429331 @default.
• W2969373323 cites W2064648264 @default.
• W2969373323 cites W2082328647 @default.
• W2969373323 cites W2106869018 @default.
• W2969373323 cites W2115579705 @default.
• W2969373323 cites W2121655616 @default.
• W2969373323 cites W2168114604 @default.
• W2969373323 cites W2169666803 @default.
• W2969373323 cites W2315560297 @default.
• W2969373323 cites W2323736331 @default.
• W2969373323 cites W2328332968 @default.
• W2969373323 cites W2511755939 @default.
• W2969373323 cites W2513151665 @default.
• W2969373323 cites W2518369513 @default.
• W2969373323 cites W2523396458 @default.
• W2969373323 cites W2577453388 @default.
• W2969373323 cites W2602602904 @default.
• W2969373323 cites W2735211627 @default.
• W2969373323 cites W2744488890 @default.
• W2969373323 cites W2791100688 @default.
• W2969373323 cites W2791547005 @default.
• W2969373323 cites W2793905111 @default.
• W2969373323 cites W2884302925 @default.
• W2969373323 cites W2905153461 @default.
• W2969373323 doi "https://doi.org/10.1136/bmjopen-2018-027860" @default.
• W2969373323 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6707666" @default.
• W2969373323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31444180" @default.
• W2969373323 hasPublicationYear "2019" @default.
• W2969373323 type Work @default.
• W2969373323 sameAs 2969373323 @default.
• W2969373323 citedByCount "18" @default.
• W2969373323 countsByYear W29693733232020 @default.
• W2969373323 countsByYear W29693733232021 @default.
• W2969373323 countsByYear W29693733232022 @default.
• W2969373323 countsByYear W29693733232023 @default.
• W2969373323 crossrefType "journal-article" @default.
• W2969373323 hasAuthorship W2969373323A5001406891 @default.
• W2969373323 hasAuthorship W2969373323A5003951535 @default.
• W2969373323 hasAuthorship W2969373323A5008940864 @default.
• W2969373323 hasAuthorship W2969373323A5010246954 @default.
• W2969373323 hasAuthorship W2969373323A5017833700 @default.
• W2969373323 hasAuthorship W2969373323A5031651345 @default.
• W2969373323 hasAuthorship W2969373323A5033637479 @default.
• W2969373323 hasAuthorship W2969373323A5037739817 @default.
• W2969373323 hasAuthorship W2969373323A5047898396 @default.
• W2969373323 hasAuthorship W2969373323A5053328244 @default.
• W2969373323 hasAuthorship W2969373323A5054505998 @default.
• W2969373323 hasAuthorship W2969373323A5060939609 @default.
• W2969373323 hasAuthorship W2969373323A5066405171 @default.
• W2969373323 hasAuthorship W2969373323A5073171755 @default.
• W2969373323 hasAuthorship W2969373323A5076457123 @default.
• W2969373323 hasAuthorship W2969373323A5081195789 @default.
• W2969373323 hasBestOaLocation W29693733231 @default.
• W2969373323 hasConcept C121608353 @default.
• W2969373323 hasConcept C126322002 @default.
• W2969373323 hasConcept C141071460 @default.
• W2969373323 hasConcept C168563851 @default.
• W2969373323 hasConcept C2775934546 @default.
• W2969373323 hasConcept C2776141087 @default.
• W2969373323 hasConcept C2776235491 @default.
• W2969373323 hasConcept C2779466945 @default.
• W2969373323 hasConcept C2780192828 @default.
• W2969373323 hasConcept C2781406297 @default.
• W2969373323 hasConcept C535046627 @default.
• W2969373323 hasConcept C71924100 @default.
• W2969373323 hasConcept C72563966 @default.
• W2969373323 hasConcept C88879693 @default.
• W2969373323 hasConceptScore W2969373323C121608353 @default.
• W2969373323 hasConceptScore W2969373323C126322002 @default.
• W2969373323 hasConceptScore W2969373323C141071460 @default.
• W2969373323 hasConceptScore W2969373323C168563851 @default.

• next